Menu Search
Equities

Marinus Pharmaceuticals Inc

0JYL:LSE

Marinus Pharmaceuticals Inc

Actions
  • Price (USD)0.323
  • Today's Change0.00 / 0.00%
  • Shares traded320.00
  • 1 Year change-94.69%
  • Beta--
Data delayed at least 20 minutes, as of Nov 25 2024 16:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

  • Revenue in USD (TTM)31.47m
  • Net income in USD-140.49m
  • Incorporated2003
  • Employees165.00
  • Location
    Marinus Pharmaceuticals Inc5 Radnor Corporate Center Suite 500100 Matsonford RdRADNOR 19087United StatesUSA
  • Phone+1 (484) 801-4670
  • Fax+1 (302) 655-5049
  • Websitehttps://marinuspharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.